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Abstract Rheumatoid arthritis (RA) is an autoimmune dis-
ease characterized by joint inflammation. The presence of
autoantibodies in the sera of RA patients has provided many
clues to the underlying disease pathophysiology. Based on the
presence of several autoantibodies like rheumatoid factor
(RF), anti-citrullinated protein antibodies (ACPA), anti-
carbamylated protein antibodies (anti-CarP), and more recent-
ly anti-acetylated protein antibodies RA can be subdivided
into seropositive and seronegative disease. The formation of
these autoantibodies is associated with both genetic and envi-
ronmental risk factors for RA, like specific human leukocyte
antigen (HLA) alleles and smoking. Autoantibodies can be
detected many years before disease onset in a subset of pa-
tients, suggesting a sequence of events in which the first au-
toantibodies develop in predisposed hosts, before an inflam-
matory response ensues leading to clinically apparent arthritis.
Research on the characteristics and effector functions of these
autoantibodies might provide more insight in pathophysiolog-
ical processes underlying arthritis in RA. Recent data suggests
that ACPA might play a role in perpetuating inflammation
once it has developed. Furthermore, pathophysiological
mechanisms have been discovered supporting a direct link
between the presence of ACPA and both bone erosions and
pain in RA patients. In conclusion, investigating the possible
pathogenic potential of autoantibodies might lead to improved
understanding of the underlying pathophysiological processes
in rheumatoid arthritis.
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Pathophysiology
Rheumatoid arthritis (RA) is a chronic autoimmune disease
primarily affecting the joints. RA is a heterogeneous disease
that encompasses several disease subsets with probable differ-
ences in underlying pathophysiology. Via a final common
inflammatory pathway, these different pathophysiological
pathways might lead to a similar clinical presentation of ar-
thritis. The best-known subdivision in RA is between ACPA-
positive and ACPA-negative disease, which differ in both risk
factors and clinical outcomes [1]. This review focuses on the
role of autoantibodies in the pathophysiology of RA. First, the
relation between autoantibodies and known risk factors for
RA will be discussed. Thereafter, the specific characteristics
of the autoantibody response and the pathogenic potential of
the different autoantibodies are reviewed.
Several autoantibodies can be detected in serum of RA
patients, of which rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA) are the most promi-
nent. More recently, antibodies against additional
posttranslationally modified proteins were discovered, such
as anti-carbamylated protein antibodies (anti-CarP) [2] and
anti-acetylated protein antibodies [3]. In recent years, most
research on the role of autoantibodies in disease pathophysi-
ology has focused on ACPA, which are directed against
citrullinated proteins. Citrullination is a reaction mediated by
peptidyl-arginine deiminase (PAD) enzymes, which convert
the DNA-encoded amino acid arginine into citrulline. This
posttranslational modification occurs under both physiologi-
cal and pathological circumstances. Multiple known risk
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factors for RA are hypothesized to be related to the develop-
ment of the immune response against citrullinated proteins
and thus ACPA formation. In the next section, hypotheses
linking RA risk factors to autoantibody formation are
discussed. Subsequently, the specific characteristics of the dif-
ferent autoantibodies responses are elaborated.
Risk factors
Genetic risk factors
Rheumatoid arthritis affects approximately 0.5 to 1% of the
population. Ample research has been performed on risk fac-
tors for this disease, since it is hoped that this might provide
more insight into the involved inflammatory processes and
possible opportunities for prevention or treatment of RA.
Several environmental and genetic risk factors increasing dis-
ease susceptibility have been identified. Twin studies have
shown that genetic variation accounts for 50 to 60% of the
risk on RA development [4]. The HLA-DRB1*01, *04, and
*10 alleles are the strongest genetic risk factor for RA devel-
opment, in particular for ACPA-positive RA [5]. Most HLA-
DRB1 alleles associated with RA share an identical amino
acid sequence in the peptide-binding groove, which has been
termed the shared epitope (SE) [6]. The similarity in sequence
has led to the hypothesis that all predisposing HLA molecules
containing the SE sequence might present specific
Barthritogenic^ peptides, which could lead to a joint-specific
autoimmune reaction. Given the strong association with
ACPA-positive RA, it has been postulated that peptides pre-
sented by SE-containing alleles might be citrullinated. It was
indeed shown that conversion of an arginine into a citrulline at
the peptide-SE interaction site significantly increased the af-
finity of the peptide for theMHCmolecule [7]. Furthermore, a
study focusing on the crystal structure of the HLA-DRB1
antigen complex found that SE alleles preferentially bound
citrullinated peptides, whereas other alleles bound both citrul-
line and arginine [8]. The high affinity of SE for citrullinated
peptides could increase the amount of HLA peptide com-
plexes on the surface of antigen-presenting cells (APCs), thus
leading to a (possible joint-specific) T cell response [7].
However, it has proven difficult to identify the exact
peptide-binding motifs for these SE molecules. Therefore,
the exact peptides bound by HLA-SE molecules in vivo re-
main subject to further investigation.
Other theories on the role of the SE in RA development
have also been postulated, since SE alleles also have another
function as a ligand for cell surface calreticulin (CRT), an
innate immune receptor present on most human cells and spe-
cifically on dendritic cells. The SE-CRT interaction, which is
more potent when CRT is citrullinated, is able to initiate a
signal transduction cascade changing the phenotype of the
dendritic cell and thereby leading to skewing of T cell re-
sponses to the T helper 17 (Th17) subset and reduced regula-
tory T cell formation [9, 10]. However, the exact role of SE-
CRT interaction to RA pathogenesis needs to be further inves-
tigated. The different hypotheses on the function of SE in RA
are not mutually exclusive, and their relative importance re-
mains unclear.
Besides the HLA region, multiple single nucleotide poly-
morphisms (SNP) are associated with rheumatoid arthritis
[11]. Among these loci is the PTPN22 gene, the second most
potent genetic risk factor for RA development [12]. PTPN22
encodes a protein tyrosine phosphatase (PTPs), which is in-
volved in T cell and B cell antigen receptor (TCR) signaling.
Thus, it may not be surprising that this gene is associated with
multiple autoimmune diseases [13]. Recently, the PTPN22
risk allele was also linked to hypercitrullination of peripheral
blood mononuclear cells (PBMCs), a process mediated by
PAD enzymes [14]. The relationship between PTPN22 and
both hypercitrullination and T and B cell receptor signaling
offers new research opportunities to gain more insight in the
complex events taking place during the preclinical phase of
RA.
Smoking
Of the environmental risk factors for (ACPA-positive) RA,
smoking is the most important. Several theories exist on
how smoking might predispose to RA. Smoking leads to
higher expression of the PAD2 enzyme, increasing the level
of citrullination in the lung [15]. However, it is still unclear
how tolerance against citrullinated proteins is broken and
ACPAs are produced, since citrullination also occurs in phys-
iological conditions. (Hyper) citrullination alone is therefore
not enough to cause a break of tolerance and leads to autoim-
munity. A gene-environment interaction has been reported
between HLA-DR SE alleles, and, to a lesser extent,
PTPN22 and smoking. This interaction suggests interplay be-
tween T cells (on which these genetic risk factors exert their
effect) and the abundance of citrullinated antigens (influenced
by smoking), leading to a break of tolerance [16, 17].
Citrulline-specific T cells have been described in both SE-
positive healthy individuals and in RA patients. However,
the immune response in RA patients was more pro-
inflammatory with a significantly higher amount of cells and
skewing to a T helper 1 (Th1) memory phenotype [18, 19].
The microbiome
Recently, the microbiome has received much attention as a
possible important player in the pathophysiology of a wide
variety of diseases. Also, in rheumatoid arthritis, a role for
the oral and gut microbiome has been indicated. RA patients
can be distinguished from healthy controls based on
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alterations and dysbiosis of the microbiome, for example, re-
garding clostridium, lactobacillus, and bifidobacteria species
in the gut microbiota [20]. Alterations in the microbiome have
not been found to induce arthritis, but could worsen or allevi-
ate arthritis. It has been hypothesized that dysbiosis of the
microbiome could lead to local inflammation, loss of barrier
function, and bacterial translocation from mucosa to the
bloodstream. Some bacterial cell wall components might mo-
lecularly mimic human autoantigens, triggering an immune
response also directed against the joint [20, 21].
In this light, the epidemiological association between rheu-
matoid arthritis and periodontitis, a bacterial-induced chronic
inflammation of the gums, is intriguing. The bacterium
Porphyromonas gingivalis, causing severe periodontitis,
might provide a pathophysiological explanation for this epi-
demiological relation, since ACPAs can bind citrullinated
alpha-enolase of P. gingivalis [22]. Furthermore, this microor-
ganism expresses a PAD enzyme, providing a source of
citrullinated antigens in a pro-inflammatory environment.
The proteins citrullinated by bacterial PAD might evoke an
immune response that is cross-reactive with self-peptides, thus
causing a break of tolerance [23]. However, mammalian
calcium-dependent PAD enzymes citrullinate specific argi-
nine residues within polypeptide chains (endocitrullination),
while the PAD enzyme of P. gingivalis modifies only C-
terminal arginines [24]. Therefore, antigens citrullinated by
P. gingivalis PAD differ significantly from citrullinated self-
antigens, which renders this molecular mimicry theory subject
to debate.
New insights into this matter were provided by a recent
study, which found citrullinated peptides showing
endocitrullination in gingival crevicular fluid (GCF) of pa-
tients with periodontal disease. Only a single pathogen related
to periodontitis, Aggregatibacter actinomycetemcomitans
(Aa), has the potential to dysregulate citrullination by human
PAD enzymes, leading to endocitrullination. Pore-forming
toxin leukotoxin A (LtxA), produced by Aa, mediates this
process by binding to β2 integrin (CD18) on neutrophils,
leading to an influx of extracellular calcium and
hypercitrullination of intracellular proteins by the cells’ own
calcium-dependent PAD enzymes. In RA patients, the pres-
ence of anti-LtxA antibodies was significantly associated with
both ACPA and RF positivity. Furthermore, the association
between HLA-SE alleles and ACPA was exclusively found
in the concomitant presence of anti-LtxA antibodies,
supporting a role for LtxA and Aa in disease development.
This theory onAa-mediated hypercitrullination in human cells
poses a new interesting mechanism for the generation of
citrullinated autoantigens independent of molecular mimicry
or citrullination by bacterial PAD enzymes [24]. Although this
theory may provide evidence for the generation of autoanti-
bodies, it does not provide a theoretical framework how anti-
bodies induce arthritis.
Autoantibodies in RA
It is estimated that 50–80% of RA patients harbor autoanti-
bodies [1]. As described above, the presence of autoantibodies
has allowed the identification of subgroups of RA patients that
are not only more homogenous with regard to risk factors but
also regarding the clinical disease course. RF, an autoantibody
directed against the Fc part of human IgG, was the first auto-
antibody system to be described in RA. The presence of RF
was considered so characteristic for RA that it was included in
the 1987 ACR classification criteria for RA, despite its sub-
optimal specificity. Several decades later the more RA-
specific ACPA were discovered [25, 26]. In the ACR-
EULAR 2010 classification criteria for RA, both RF and
ACPA have been included. More recently, antibodies against
other posttranslationally modified proteins, i.e., carbamylated
[2] and acetylated proteins were identified [3]. Seropositive
RA is associated with increased radiographic progression and
joint damage [27], while seronegative RA patients have higher
inflammation parameters at presentation [28]. Furthermore,
not only positivity for a single autoantibody but rather the
conjoined presence of multiple autoantibodies might be rele-
vant for characterizing distinct phenotypes of RA patients
[29]. Autoantibodies not merely provide useful information
on disease outcome but also offer insights into the develop-
ment of RA. Research on the different autoantibodies and their
characteristics has led to better understanding of the underly-
ing pathophysiological processes in rheumatoid arthritis.
Anti-citrullinated protein antibodies
As described earlier, citrullinated peptides are generated in
response to a posttranslational modification mediated by
PAD enzymes. Multiple antibody isotypes including IgG,
IgA, and IgM directed against these citrullinated peptides are
detected in RA [30]. The presence of ACPA IgA is in line with
the hypothesis that ACPA is related to smoking ormicrobiome
dysbiosis, as IgA is related to a mucosal origin of the immune
response. Synovial fluid from inflamed RA joints contains
citrullinated proteins, suggesting that ACPA could bind to
these antigens in the joint and possibly increase local inflam-
mation [31]. A putative target protein of ACPA is vimentin. In
collagen-induced arthritis (CIA), mouse models passive trans-
fer of ACPA cannot cause synovitis, although it can worsen
preexistent synovitis [32]. Therefore, it is suggested that mul-
tiple Bhits^ are necessary for the development of RA. A hy-
pothesis is that autoantibodies might specifically lead to non-
resolving and chronicity of a normally temporary immune
response, for example, after trauma or infection.
How might ACPA lead to inflammation? This could be
mediated via binding to Fc receptors or complement activa-
tion, which is described in more detail below. Furthermore, to
answer this question, the molecular structure of ACPA and
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specifically their glycosylation has been studied in depth over
the past years. Autoantibodies in general are glycoproteins,
meaning carbohydrate chains are attached to both the Fc and
the Fab region of the antibody, which is essential for immune
effector functions. The Fc region of ACPA has a lower level of
galactosylation and sialylation compared to IgG antibodies
against recall antigens [33]. Less sialylation of antibodies in
immune complexes can drive osteoclastogenesis in vitro and
in vivo through altered FcγR signaling. Moreover, RA pa-
tients with low levels of ACPA-IgG Fc sialylation had lower
bone volumes and trabecula numbers [34]. Thus, the specific
Fc glycan signature of ACPA could influence their ability to
contribute to disease pathophysiology.
Strikingly, the glycosylation of ACPA is not only distinct
from other antibodies in the Fc part but ACPA also more
frequently have N-linked glycans in their variable domains.
The prevalence of these glycans is markedly increased and
they also differ in structure, with Fab glycans of ACPA having
more galactose, sialic acid, and fucose residues compared to
control IgG [35]. The high galactosylation and sialylation
levels of the Fab-linked glycans are in marked contrast to
the lower level of galactosylation and sialylation detected in
the Fc part of ACPA-IgG. It remains unclear how these dis-
tinct ACPA glycosylation patterns arise, but exposure of the B
cell to environmental factors such as cytokines is likely to be
of importance. The influence of increased Fab glycosylation
on ACPA effector functions remains an area of further inves-
tigation, but it is speculated that Fab glycosylation might af-
fect the antibody half-life time or antibody-antigen binding
[35].
Anti-carbamylated protein antibodies
Anti-carbamylated protein (anti-CarP) antibodies also belong
to the group of anti-posttranslationally modified protein anti-
bodies (AMPA) that have been described in RA.
Carbamylation is a chemical reaction mediated by cyanide
in which a lysine is converted into a homocitrulline. Certain
conditions, for example, renal disease, smoking, and inflam-
mation can increase cyanide levels and thus carbamylation
[36]. Similar to citrullination, increased carbamylation alone
does not seem to be sufficient to break tolerance and induce
autoimmunity. Only 12% of patients with renal disease harbor
anti-CarP antibodies compared to approximately 44% of RA
patients [37]. Smoking might contribute to the break of toler-
ance as a recent study showed that smoking broadened the
immune response against carbamylated vimentin in mice
models, but epidemiological research failed to show an asso-
ciation between anti-CarP and smoking in RA patients [38,
39]. The importance of smoking and other (environmental or
genetic) factors necessary to break tolerance against
carbamylated proteins such a fibrinogen remains to be eluci-
dated. Although the molecular structures of homocitrulline
and citrulline are very alike, ACPA and anti-CarP are distinct
autoantibody classes, with anti-CarP being present in both
ACPA-positive and ACPA-negative patients [2]. Moreover,
anti-CarP is associated with radiographic progression in pa-
tients negative for RF and ACPA. Diagnostic classification of
RA patients did not improve by adding anti-CarP testing, as
RF and ACPA are already good predictors for disease [40].
Assays to test for the presence of anti-CarP most often use
fetal calf serum (FCS), containing a mixture of carbamylated
proteins. The exact autoantigens that anti-CarP bind in vivo
remains unclear.
Anti-acetylated protein antibodies
The latest addition to AMPAs in RA patients is anti-acetylated
protein antibodies which have been described in approximate-
ly 40% of RA patients, mainly in the ACPA-positive group.
Detection rates in seronegative RA patients were comparable
to patients with resolving arthritis, rendering it unlikely that
these antibodies will be a new biomarker helpful for diagnos-
ing RA [3]. However, anti-acetylated protein antibodies might
provide useful new insights in pathophysiology, especially in
the era in which the microbiome seems to become increasing-
ly important. Acetylation is an enzymatic process, which can
be affected by bacteria, although the underlying mechanism is
unclear. Therefore, anti-acetylated antibodies could provide a
possible new link between microbiome dysbiosis and the de-
velopment of autoimmunity in RA [3, 41].
Development of the autoantibody response over time
The presence of the different autoantibodies in serum of
(future) RA patients can be detected years before actual dis-
ease onset [42–44]. Most research on the details of the auto-
antibodies response prior to clinical disease manifestation is
done on ACPA. From all RA patients, 50% presents with
ACPA. About 4 years before disease onset, 50% of the pa-
tients that will be ACPA positive will harbor ACPA. At that
time point, the ACPA levels start to increase. The profile of
citrullinated antigens recognized expands extensively and
isotype switching occurs. These events predict RA develop-
ment in patients with undifferentiated arthritis and correlate
with a rise in inflammatory cytokine levels [45–49]. Also,
the Fc glycosylation pattern changes before disease onset.
Galactosylation decreases while fucosylation increases, lead-
ing towards a more pro-inflammatory phenotype of the anti-
bodies [50].
There is one feature of ACPA, which strikingly differs from
the normal development of antibody responses. In general,
during B cell maturation, class switching, somatic
hypermutation, and affinity maturation are physiological pro-
cesses occurring in germinal centers. B cells producing anti-
bodies with sufficient avidity will proliferate, improving the
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efficacy of the immune response. In contrast to an immune
response against recall antigens, the avidity maturation of
ACPA is very limited, resulting in low avidity antibodies
[51]. This is interesting as it suggests that isotype switching
and avidity maturation of ACPA are relatively uncoupled.
Within ACPA-positive patients, those with lower avidity,
ACPA have increased joint destruction compared to patients
with higher avidity ACPA, which might be mediated via a
higher potency to activate complement [52].
After the disease has become clinically apparent, the ACPA
profile and phenotype remains stable over time [45, 49]. The
overall development of the autoantibody response over time
raises many questions: it is for example thus far unclear which
factors are involved in the maturation of the response before
disease onset and what the role of this maturation is in disease
onset.
Pathogenic potential of autoantibodies
Several features of the anti-citrulline immune response, such
as the expansion of the ACPA repertoire before disease onset
and the association of autoantibodies with radiographic pro-
gression, suggest a possible role in disease pathology. In ad-
dition, B cell depletion with rituximab is effective in RA pa-
tients, to a greater extent in ACPA- and RF-positive cases,
arguing in favor of a role of B cells (and perhaps the autoan-
tibodies they produce) in disease pathogenesis [53]. There are
thus several lines of evidence that autoantibodies play a path-
ogenic role in RA. In the next section, several hypotheses are
discussed regarding mechanisms by which autoantibodies
might lead to ongoing inflammation and RA symptoms. In
Fig. 1, the model on the possible role of autoantibodies in
disease pathophysiology of RA, as discussed in this review,
is depicted.
Binding to Fc receptors
In general, antibodies exert an effect on other cells via Fc
receptor binding. Similar to recall antigen immune com-
plexes (ICs), immune complexes containing ACPA and
citrullinated fibrinogen are able to stimulate TNF secretion
via stimulation of Fcγ receptors on macrophages [54, 55].
The effector functions of the ACPA ICs can be modified by
the presence of RF-IgM or RF-IgA, which boosts the Fcγ
receptor-mediated immune response and increases comple-
ment activation [56]. This suggests that there may be a syn-
ergetic role of ACPA and RF in RA pathophysiology, which
is supported by epidemiological studies showing that the
combination of ACPA and RF is associated with higher
disease activity [57].
Complement activation
Another main effector function of antibodies is complement
activation. The complement system can be activated via three
pathways: the classical pathway (initiated by C1q), the alter-
native pathway (initiated by C3), and the lectin pathway (ini-
tiated by mannose-binding lectin (MBL)), which all lead to
opsonisation, formation of the membrane attack complex and
chemotaxis. In synovial fluid of RA patients, complement
levels are reduced, while complement cleavage products are
increased, indicating enhanced complement activation. It has
been shown that ACPA have the ability to recruit complement
via both the classical and alternative pathways, but not via the
lectin pathway [58]. Taken together, the evidence suggests
that ACPA have the potential to augment the immune re-
sponse in RA by both Fcγ receptor binding and complement
activation.
Neutrophil extracellular trap formation in RA
The augmented generation of neutrophil extracellular traps
(NETs) is another manner in which ACPA and/or RF antibod-
ies could affect disease development or persistence. NETs are
composed of highly condensed chromatin and are expelled by
neutrophils to trap and kill pathogens. NETosis by both circu-
lating and synovial fluid neutrophils is enhanced in RA pa-
tients compared to healthy controls. The relation between
NETosis and autoantibodies is interesting, as NETosis ex-
poses autoantigens, i.e., citrullinated self-proteins, in a pro-
inflammatory environment [59]. Therefore, amplified
citrullinated autoantigen exposure via NETosis might be in-
volved in promoting autoantibody generation and production
in predisposed hosts. It was shown that citrullinated peptides
derived from deiminated histones, a component of NETs, are
targeted by ACPAs [60]. B cells differentiated from synovial
ectopic lymphoid tissue were reactive against the citrullinated
histones exposed during NETosis [61]. On the other hand,
ACPA can stimulate NETosis. NETs trigger inflammatory re-
sponses in synovial fibroblasts, including induction of IL-6,
IL-8, chemokines, and adhesion molecules. ACPA might thus
enhance local inflammation by increasing NETosis. Taken
together, aberrant NETosis might fuel the ongoing ACPA re-
sponse and leads to a circular non-resolving pro-inflammatory
immune response, by which RA is characterized [59].
Bone erosion: osteoclast activation
Seropositive RA is associated with increased damage to joints,
which is commonly measured as radiographic progression
[62, 63]. It has been proposed that ACPA may directly affect
osteoclasts and thereby lead to the formation of bone erosions.
ACPA have indeed been described to bind to the osteoclast
surface and enhance differentiation of osteoclast precursors
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in vitro and in vivo. Adoptive transfer of ACPA has also led to
increased bone resorption in mice models, although this
process seemed to differ from the joint damage in RA [64].
Recently, a mediating effect of IL-8 in the relation between
Fig. 1 Model of the possible role
of autoantibodies in disease
pathophysiology. Genetic and
environmental risk factors might






are produced (ao ACPA) which
can activate other (immune) cells
via Fc receptors and stimulate
cytokine production. The
underlying inflammatory cascade
eventually results in clinically
apparent arthritis. AMPA anti-
modified protein antibodies
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ACPA, stimulation of osteoclasts, and bone erosions was pro-
posed. The finding that an IL-8 antagonist could prevent bone
loss in vitro in humans and in vivo in mice supports the hy-
pothesis that ACPA is directly linked to formation of bone
erosions via IL-8 induction [65]. This hypothesis about
ACPA and bone destruction is supported by preliminary data,
but many questions, for example, regarding the epitopes on
osteoclasts that ACPA bind to and the fine specificities of
ACPA mediating the effect on bone erosions, have yet to be
answered. It will be intriguing to see how this field will further
develop.
Pain
Not only radiographic progression but also chronic pain is a
significant clinical problem in RA. It was investigatedwhether
autoantibodies might also (partly) provoke these symptoms.
Mouse models injected with ACPAs were found to display
lasting pain-like behavior, while no sign of inflammation
was present. The injected ACPAs bound surface epitopes on
osteoclasts and osteoclast precursors in mouse bone marrow,
subchondral bone, and epiphyseal plate. These activated oste-
oclasts express CXCL1 (the mouse analogue of IL-8 de-
scribed earlier), whichmight mediate the effect on nociception
[66]. This research proposes a novel theory that the presence
of autoantibodies might directly contribute to arthralgia, a
symptom often present before arthritis in RA.
Final common inflammatory pathway
Described above are various scenarios about how autoanti-
bodies could be involved in the pathogenesis of RA, but it
has to be kept in mind that there is no definitive proof that
these autoantibodies are in fact pathogenic. In the develop-
ment of RA, a common inflammatory pathway seems to exist
leading to a similar clinical presentation in patients with and
without autoantibodies.
In this paragraph, a very brief overview of this final com-
mon pathway is given, in whichmany cell types and processes
are involved. Early in the development of arthritis, activation
of the innate immune system leads to an influx of leukocytes
into the normally sparsely populated synovial compartment
via the local expression of adhesion molecules and
chemokines [67]. Less complement factors and more comple-
ment cleavage products are found locally, indicating increased
complement use [68]. Also, the adaptive immune system is
triggered and stimulated dendritic cells as well as
costimulatory molecules are found. These circumstances fa-
cilitate activation of Th1 T helper cells [67].More recently, the
Th17 T helper cell phenotype has also been implicated as a
key driver of synovitis, as these cells are potent producers of
pro-inflammatory cytokines like IL-17A, IL-21, and TNF-α
[69]. The pro-inflammatory T cells, cytokines, and immune
complexes stimulate macrophages and fibroblast-like
synoviocytes (FLS) to produce pro-inflammatory cytokines,
like TNF-α, IL-1, IL-6, IL-15, and IL-23. In the RA joint, FLS
have proliferated and adapted a pro-inflammatory phenotype
with increased expression of chemokines, adhesion mole-
cules, and matrix metalloproteinases (MMP). MMP can lead
directly to cartilage destruction and chronic synovial inflam-
mation. Cartilage can also be affected indirectly via cytokines
leading to chondrocyte activation and tissue catabolism [70].
Besides cartilage, also bone is subject to destruction in the
joint of RA patients. Activated fibroblasts, T cells, B cells,
and macrophages can upregulate expression of RANK ligand,
leading to osteoclastogenesis and thus bone destruction [71].
The central role of cytokines in RA synovitis is further af-
firmed by the successful use of monoclonal antibodies direct-
ed against these cytokines, the most well-known being anti-
TNFα, in the treatment of RA. However, these therapies have
the major downside that they target the immune system non-
specifically, increasing the risk of infections and perhaps neo-
plasms. Therefore, research focusing on unraveling the precise
immunopathology of RA might introduce possibilities for
specific targeted therapy, which could significantly improve
care for RA patients.
Conclusion
Discoveries in recent years have shed more light on RA path-
ophysiology. Studies investigating the role of anti-
posttranslational-modified protein antibodies, especially
ACPA, have led to a better understanding of underlying path-
ophysiological processes. Autoantibody formation is associat-
ed with both genetic and environmental risk factors for RA,
like HLA-SE alleles, smoking, and microbiome dysbiosis,
offering intriguing new views on the development of RA.
Also, new hypotheses on the effector functions of the autoan-
tibodies have been postulated, indicating a role for ACPA in
both bone destruction and arthralgia. However, despite de-
scriptions of effector functions of these autoantibodies, it re-
mains unclear if they contribute directly to disease pathogen-
esis and joint inflammation. Furthermore, insights into the
immune response underlying seronegative disease remain
limited. This continues to be an interesting area for further
investigation, aiming to gain more knowledge on possible
therapeutic targets. In the past decade, great progress has been
achieved by blocking cytokines or receptors in the final in-
flammatory pathway of joint inflammation. Despite the suc-
cess of these new, biologic treatments, they generally do not
cure the disease and currently pose a substantial financial bur-
den. It is therefore to be hoped that new insights into patho-
physiology will allow us to achieve the ultimate goal of
preventing RA.
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